BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19

• 

  Opinion

  Convert nonresponder insights into smarter drug development strategies in immunology

  While agents like AbbVie’s Humira have transformed the treatment landscape, not all patients benefit equally from the drug. Better biomarker analysis and more investment in mechanistic trials can inform the development of more effective therapies with broader clinical value.

  June 18, 2026

   · 

  5 min read

   · 

  Kori Wallace
• 

  Job Trends

  On the chopping block? When layoffs may and may not lurk around the corner

  Cost cutting is just one factor driving biopharmas to whittle away at their workforces. An analyst discusses more common reasons layoffs occur and which employees are most at risk.

  June 18, 2026

   · 

  3 min read

   · 

  Angela Gabriel
• 

  Job Trends

  Ones to watch: 4 biotechs with recent Series B raises (that are also hiring)

  Biopharmas that announced Series B financing this year and are looking for employees as they grow include two companies that received $100 million or more. One has partnerships with three Big Pharmas.

  June 18, 2026

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Job Trends

  7 companies hiring in Boston

  Looking for a job in Boston? Here’s a list of 7 companies on BioSpace currently hiring biopharma roles in Boston–plus a few more hiring in Waltham and Weston.

  June 18, 2026

   · 

  1 min read

   · 

  Chantal Dresner
• 

  Approvals

  GSK, Spero’s oral antibiotic wins first FDA nod for complicated UTI

  After being rejected in June 2022, GSK paid Spero Therapeutics $66 million for an exclusive worldwide license to develop and commercialize the drug. It’s the second oral antibiotic GSK has brought to market since the beginning of last year.

  June 18, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Biogen makes up to $1B immuno play with RayThera takeover

  RayThera will bring three preclinical assets into the Biogen fold, all with anti-inflammatory activity. The most mature of these assets is expected to enter Phase 1 development in Q3.

  June 18, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pancreatic cancer

  Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution

  Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.

  June 18, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Moderna mulls deals to rescue German BioNTech plants from closure: report

  The takeovers depend on Moderna reaching an agreement with the German government, which risks losing investment from drugmakers over planned healthcare reforms.

  June 18, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  IPO tracker

  Cardio biotech Kardigan binds off $400M upsized IPO

  Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.

  June 18, 2026

   · 

  16 min read

   · 

  Editorial Team
• 

  Series A

  New biotech cAMPfield emerges with $180M to reshape IBD treatment

  Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.

  June 18, 2026

   · 

  2 min read

   · 

  Gabrielle Masson